Heart disease detection device developer Heart Test Labs raised $12 million in a private placement of common stock to support the international launch of its MyoVista product in the 1st quarter.
The round was significantly over-subscribed, Heart Test Labs said, and “provides HTL with a strong financial base entering into 2017.” The company said it is in the process of hiring sales staff as it prepares to launch its MyoVista system.
The Westlake, Texas-based company’s MyoVista is an electrocardiography device which operates on proprietary technology to aid in the early detection of heart disease.
The device operates on a standard 12-lead resting ECG and provides both a traditional ECG and proprietary informatics for early identification of ischemic and other myocardial disfunctions, according to a press release.
